Age-related Macular Degeneration Clinical Trial
Official title:
An Open Label, Pilot (Phase I/II), Dose-Escalation Safety and Tolerability Study of Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration.
Verified date | December 2017 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is assess safety, bioactivity, and maximal tolerated dose of repeated weekly intravenous infusion of combretastatin A-4 phosphate (CA4P) in patients with neovascular age-related macular degeneration
Status | Completed |
Enrollment | 8 |
Est. completion date | June 2005 |
Est. primary completion date | June 2005 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years and older |
Eligibility |
Inclusion Criteria: 1. Age 50 years or older; 2. 12-lead electrocardiogram (ECG) performed at least 2 weeks but less than 4 weeks prior to entry into the study showing a QTc <440 with no evidence of current or prior myocardial ischemia, infarction or significant arrhythmia as determined by review and signature of the cardiologist. 3. Adequate bone marrow function: Absolute granulocyte count =1500 cells/mm3; Platelet count =100,000 cells/mm3; Hemoglobin =9.0gm/ dL; 4. PT/PTT within the institution upper limit of normal (ULN) or INR <1.1 ; 5. Adequate hepatic function: Total bilirubin within the institution ULN; Alanine and aspartate aminotransferase (ALT/AST) <3 times the institutional ULN; 6. Adequate renal function: serum creatinine =2.0 mg/dL; 7. Ophthalmic criteria: 1. Best corrected visual acuity in the study eye of =20/40 and =20/800 in the fellow eye. 2. Subfoveal choroidal neovascularization (as illustrated by fluorescein angiography) secondary to age-related macular degeneration, with a total lesion size of =12 total disc areas, of which at least 50% must be active CNV. 3. Subretinal hemorrhage =50% of total lesion size; 4. For patients with minimally classic and purely occult CNV, there must be documented evidence of =2 lines of vision loss (ETDRS) during the previous 12 weeks; 5. Clear ocular media and adequate papillary dilatation to permit good quality stereoscopic fundus photography; 8. Male fertile patients must abstain from sexual intercourse or use effective birth control; 9. Women must be post-menopausal for at least 12 months prior to study entry, or surgically sterile, or must be using two forms of effective contraception. 10. Able to return for all study visits within required visit windows; 11. Be able to give written informed consent. Exclusion Criteria: 1. Previous subfoveal thermal laser therapy; 2. Any subfoveal scarring or atrophy, or >25% of the total lesion size is made up of scarring or atrophy; 3. Significant media opacities, including cataract, which can interfere with visual acuity, assessment of toxicity, or fundus photography; 4. Presence of other causes of choroidal neovascularization, including pathologic myopia (spherical equivalent of =-8.0 diopters, or axial length of =25mm), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, and multifocal choroiditis and other uveitic entities; 5. Any condition that might interfere with assessment of the progression of CNV; 6. Any intraocular surgery in the study eye within 12 weeks of screening for the study; 7. Other treatment for AMD of the study eye within 12 weeks prior to screening; 8. Known allergy to fluorescein; 9. Any current or history of significant gastrointestinal, oral, or nasal bleeding; 10. Serious intercurrent infections or other nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this therapy; 11. Grade 2 (CTC v.3.0) or greater pre-existing peripheral neuropathy; 12. Psychiatric disorders or other conditions rendering patients incapable of complying with the requirements of the protocol; 13. Pregnant or breast-feeding women; 14. History of angina, myocardial infarction, CHF, non-controlled atrial arrhythmias or clinically significant arrhythmias including conduction abnormality, nodal junctional arrhythmias and dysrhythmias, sinus bradycardia or tachycardia, supraventricular arrhythmias, atrial fibrillation or flutter, syncope or vasovagal episodes; 15. Abnormal cardiac stress test; 16. Uncontrolled hypertension (consistently >150/100mmHg irrespective of medication); 17. Uncontrolled hypokalemia and/or hypomagnesemia; 18. ECG with evidence of prior myocardial infarction, QTc > 450 msec or other clinically significant abnormalities; 19. Drug(s) known to prolong the QTc interval; 20. Patients with conditions associated with QTc prolongation; 21. Any investigational drug or device within 4 weeks prior to screening; 22. Decreased ejection fraction =50% or prior myocardial infarction. |
Country | Name | City | State |
---|---|---|---|
United States | Wilmer Eye Institute | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and Tolerability | To report frequency and severity of adverse events, as defined by the common terminology criteria of adverse events (CTCAE v.3.0; National Cancer Institute), and to determine the degree of relationship of adverse events to the study drug (CA4P). | 12 weeks after the first infusion of the Study Drug | |
Primary | Dose Limiting Toxicities (DLT) | DLT is defined as any of the following adverse events if =Grade-2 in severity: ventricular arrhythmia, second or third degree AV block, severe sinus bradycardia < 45 bpm, tachycardia >120 bpm, supraventricular arrhythmia > 24 hours, ventricular tachycardia (>9 beats in a row), any length of torsades de pointes, unexplained recurrent syncope, QTc prolongation =500 msec on > 2 consecutive ECGs, Grade-2 or greater myocardial infarction, or ocular toxicities deemed by the investigator not acceptable for the patients to receive further treatments. | 12 weeks after the first infusion of the study drug | |
Secondary | Maximum Tolerated Dose | Maximum Tolerated Dose (MTD) of intravenous infusion of combretastatin A-4 phosphate in patients with neovascular age related macular degeneration. The MTD is defined as the maximum dose level of CA4P administered at which, DLT is observed in fewer than 2 patients at a given cohort. | 12 weeks after the first infusion of the study drug | |
Secondary | Change in Best Corrected Visual Acuity | Difference change from baseline in Best corrected visual acuity, as measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol, at week 4 and week 12. | 4 and 12 weeks after first infusion of the study drug | |
Secondary | Change in Central Retinal Thickness | Difference change from baseline in central retinal thickness as measured by Optical Coherence Tomography at week 4 and week 12. | 4 and 12 weeks following the first infusion of CA4P |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05984927 -
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05536297 -
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
|
Phase 3 | |
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Completed |
NCT04005352 -
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
|
Phase 3 | |
Withdrawn |
NCT02873351 -
A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration
|
Phase 2 | |
Active, not recruiting |
NCT02802657 -
Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration
|
Phase 4 | |
Not yet recruiting |
NCT02864472 -
Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose
|
Phase 4 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT02035722 -
Intravitreal Injections-related Anxiety
|
Phase 2/Phase 3 | |
Completed |
NCT01445548 -
Sirolimus for Advanced Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT01175395 -
20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01048476 -
Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01174407 -
Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration
|
N/A | |
Terminated |
NCT00712491 -
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT00345176 -
Age-Related Eye Disease Study 2 (AREDS2)
|
Phase 3 | |
Completed |
NCT02140151 -
Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT02555306 -
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Recruiting |
NCT04796545 -
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
|
N/A | |
Completed |
NCT03166202 -
Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator
|
||
Completed |
NCT01397409 -
Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
|
Phase 2 |